Logo image of RCAT

RED CAT HOLDINGS INC (RCAT) Stock Fundamental Analysis

USA - NASDAQ:RCAT - US75644T1007 - Common Stock

15.0081 USD
+2.12 (+16.43%)
Last: 10/6/2025, 2:50:09 PM
Fundamental Rating

3

Taking everything into account, RCAT scores 3 out of 10 in our fundamental rating. RCAT was compared to 124 industry peers in the Electronic Equipment, Instruments & Components industry. RCAT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RCAT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RCAT had negative earnings in the past year.
In the past year RCAT has reported a negative cash flow from operations.
RCAT had negative earnings in each of the past 5 years.
RCAT had a negative operating cash flow in each of the past 5 years.
RCAT Yearly Net Income VS EBIT VS OCF VS FCFRCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

RCAT's Return On Assets of -55.70% is on the low side compared to the rest of the industry. RCAT is outperformed by 86.29% of its industry peers.
RCAT has a worse Return On Equity (-70.74%) than 78.23% of its industry peers.
Industry RankSector Rank
ROA -55.7%
ROE -70.74%
ROIC N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
RCAT Yearly ROA, ROE, ROICRCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCAT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCAT Yearly Profit, Operating, Gross MarginsRCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0 0 0 0 0 0 0 0 0 0

More info and screens

5

2. Health

2.1 Basic Checks

RCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
RCAT has more shares outstanding than it did 1 year ago.
RCAT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for RCAT has been reduced compared to a year ago.
RCAT Yearly Shares OutstandingRCAT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RCAT Yearly Total Debt VS Total AssetsRCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 33.06 indicates that RCAT is not in any danger for bankruptcy at the moment.
RCAT has a better Altman-Z score (33.06) than 95.97% of its industry peers.
A Debt/Equity ratio of 0.20 indicates that RCAT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.20, RCAT is in line with its industry, outperforming 46.77% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 33.06
ROIC/WACCN/A
WACC9.11%
RCAT Yearly LT Debt VS Equity VS FCFRCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 3.80 indicates that RCAT has no problem at all paying its short term obligations.
With a decent Current ratio value of 3.80, RCAT is doing good in the industry, outperforming 75.81% of the companies in the same industry.
A Quick Ratio of 2.92 indicates that RCAT has no problem at all paying its short term obligations.
With a decent Quick ratio value of 2.92, RCAT is doing good in the industry, outperforming 74.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.8
Quick Ratio 2.92
RCAT Yearly Current Assets VS Current LiabilitesRCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

RCAT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.31%.
Looking at the last year, RCAT shows a very negative growth in Revenue. The Revenue has decreased by -53.12% in the last year.
Measured over the past years, RCAT shows a very strong growth in Revenue. The Revenue has been growing by 176.68% on average per year.
EPS 1Y (TTM)-17.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)-53.12%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-18.11%

3.2 Future

RCAT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.49% yearly.
Based on estimates for the next years, RCAT will show a very strong growth in Revenue. The Revenue will grow by 123.37% on average per year.
EPS Next Y-16.45%
EPS Next 2Y45.28%
EPS Next 3Y39.49%
EPS Next 5YN/A
Revenue Next Year321.55%
Revenue Next 2Y184.14%
Revenue Next 3Y123.37%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RCAT Yearly Revenue VS EstimatesRCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
RCAT Yearly EPS VS EstimatesRCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RCAT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 339.58, the valuation of RCAT can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as RCAT.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.32, RCAT is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 339.58
RCAT Price Earnings VS Forward Price EarningsRCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCAT Per share dataRCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

RCAT's earnings are expected to grow with 39.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.28%
EPS Next 3Y39.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCAT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RED CAT HOLDINGS INC

NASDAQ:RCAT (10/6/2025, 2:50:09 PM)

15.0081

+2.12 (+16.43%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)09-23 2025-09-23
Earnings (Next)12-15 2025-12-15
Inst Owners28.63%
Inst Owner Change0%
Ins Owners13.91%
Ins Owner Change0.41%
Market Cap1.77B
Analysts84.44
Price Target15.64 (4.21%)
Short Float %21.86%
Short Ratio1.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-89.99%
Min EPS beat(2)-152.1%
Max EPS beat(2)-27.88%
EPS beat(4)0
Avg EPS beat(4)-100.39%
Min EPS beat(4)-152.1%
Max EPS beat(4)-27.88%
EPS beat(8)1
Avg EPS beat(8)-86.46%
EPS beat(12)2
Avg EPS beat(12)-132.75%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-46.29%
Min Revenue beat(2)-59.15%
Max Revenue beat(2)-33.43%
Revenue beat(4)0
Avg Revenue beat(4)-25.15%
Min Revenue beat(4)-59.15%
Max Revenue beat(4)-1.15%
Revenue beat(8)2
Avg Revenue beat(8)-16.41%
Revenue beat(12)3
Avg Revenue beat(12)-25.46%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.98%
PT rev (3m)15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-160%
EPS NY rev (1m)-7.88%
EPS NY rev (3m)-16.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.8%
Revenue NY rev (1m)-4.54%
Revenue NY rev (3m)-4.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 339.58
P/S 255.87
P/FCF N/A
P/OCF N/A
P/B 18.53
P/tB 25.22
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)0.04
Fwd EY0.29%
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0.06
BVpS0.81
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.7%
ROE -70.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.37%
Cap/Sales 9.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.8
Quick Ratio 2.92
Altman-Z 33.06
F-Score3
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)137.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.59%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-16.45%
EPS Next 2Y45.28%
EPS Next 3Y39.49%
EPS Next 5YN/A
Revenue 1Y (TTM)-53.12%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-18.11%
Revenue Next Year321.55%
Revenue Next 2Y184.14%
Revenue Next 3Y123.37%
Revenue Next 5YN/A
EBIT growth 1Y-73.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.76%
EBIT Next 3Y56.58%
EBIT Next 5YN/A
FCF growth 1Y-152.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-154.15%
OCF growth 3YN/A
OCF growth 5YN/A